Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$BNTX Plan to supply 900M doses of COMIRNATY to the European Commission. source
Pipeline Updates
$ASND Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile. source
$HRTX PDUFA date for HTX-011 set at May 12, 2021. source
$IMGN Mirvetuximab FORWARD II study selected to present at ASCO on June 4-8. source
$KOD Plan to initiate two pivotal Phase 3 studies and complete additional pivotal study of KSI-301 in 2021. source
$SAVA Initiates Cognition Maintenance Study to evaluate simufilam in patients with Alzheimer's disease. source
$OSMT Upneeq wins 2021 MedTech Breakthrough Award. source
$CUE Reports confirmed partial response in Phase 1 monotherapy study of CUE-101. source
$LQDA Resubmitted NDA on 5/7/21 for LIQ861 which included additional chemistry, manufacturing, and controls clarification. source
$MBIO FDA has accepted IND application to initiate Phase 1/2 study of MB-106. source
$ALXO Announces first patient dosed in Phase 2 ASPEN-03 study. source
$GTHX Initiates PRESERVE 4 Phase 2 study of COSELA. source
$EGRX Announces TREAKISYM RI has been filed with PMDA in Japan. source
$FBIO Enters into licensing agreement with Fuji Yakuhin Co. Ltd. for development of Dotinurad. source
$AUPH Phase 3 AURORA 1 study results published in The Lance. source
$CMPI Expands vidutolimod program into non-melanoma skin cancers in combo with Libtayo. source
$IDYA Announced dose expansion in Phase 1/2 Darovasertib and Crizotinib combo study. source
Financial Updates
$BNTX Plan to establish first regional headquarters for southeast Asian in Singapore. source
$DVAX Announces proposed private offering of $200M of convertible senior notes. source
$INSM Intends to offer and sell $250M of its common stock. source